Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares
Virax Biolabs Group (Nasdaq: VRAX), a biotechnology company focusing on immune response detection and viral disease diagnostics, announced a $5 million registered direct offering of 1,108,892 ordinary shares at $4.50 per share.
H.C. Wainwright & Co. is the exclusive placement agent. The offering is set to close around August 23, 2024, pending customary conditions.
Gross proceeds are estimated at $5 million, before placement fees and expenses. Net proceeds are intended for working capital and general corporate purposes.
The offering is conducted under a shelf registration statement (Form F-3, Registration No. 333-275893), previously filed with the SEC and declared effective on December 15, 2023. A final prospectus supplement and the base prospectus will be filed and made available on the SEC website.
Virax Biolabs Group (Nasdaq: VRAX), un'azienda biotecnologica focalizzata sulla rilevazione della risposta immunitaria e sulla diagnosi delle malattie virali, ha annunciato un'offerta diretta registrata di 5 milioni di dollari per 1.108.892 azioni ordinarie a 4,50 dollari per azione.
H.C. Wainwright & Co. è l'agente di collocamento esclusivo. L'offerta dovrebbe chiudersi intorno al 23 agosto 2024, previo rispetto delle condizioni di prassi.
Gli incassi lordi sono stimati in 5 milioni di dollari, al netto delle commissioni di collocamento e delle spese. I proventi netti saranno destinati a capitale operativo e scopi aziendali generali.
L'offerta viene effettuata ai sensi di una dichiarazione di registrazione a scaffale (Modulo F-3, Numero di registrazione 333-275893), precedentemente depositata presso la SEC e dichiarata efficace il 15 dicembre 2023. Un supplemento al prospetto finale e il prospetto base saranno depositati e resi disponibili sul sito web della SEC.
Virax Biolabs Group (Nasdaq: VRAX), una empresa de biotecnología centrada en la detección de la respuesta inmune y el diagnóstico de enfermedades virales, anunció una oferta directa registrada de 5 millones de dólares por 1.108.892 acciones ordinarias a 4,50 dólares por acción.
H.C. Wainwright & Co. es el agente exclusivo de colocación. Se espera que la oferta se cierre alrededor del 23 de agosto de 2024, sujeta a las condiciones habituales.
Los ingresos brutos se estiman en 5 millones de dólares, antes de comisiones y gastos de colocación. Los ingresos netos se destinarán a capital de trabajo y fines corporativos generales.
La oferta se realiza bajo una declaración de registro de estante (Formulario F-3, Número de registro 333-275893), presentada anteriormente ante la SEC y declarada efectiva el 15 de diciembre de 2023. Se presentará un suplemento al prospecto final y el prospecto base estará disponible en el sitio web de la SEC.
Virax Biolabs Group (Nasdaq: VRAX), 면역 반응 탐지 및 바이러스 질병 진단에 중점을 둔 생명공학 회사가 500만 달러의 등록 직접 제안을 발표했습니다. 이 제안은 1,108,892주의 보통주가 1주당 4.50달러로 제공됩니다.
H.C. Wainwright & Co.는 독점 배치 에이전트입니다. 제안은 관례적인 조건이 충족되면 2024년 8월 23일경에 마감될 예정입니다.
총 수익은 배치 수수료 및 비용 전 500만 달러로 추산됩니다. 순수익은 운영 자본 및 일반 기업 목적에 사용할 예정입니다.
제안은 선반 등록명세서 (폼 F-3, 등록번호 333-275893) 하에 수행되며, 이는 SEC에 이전에 제출되었으며 2023년 12월 15일에 효력을 발휘했습니다. 최종 전망 보충서와 기본 전망서는 SEC 웹사이트에 제출되고 제공될 예정입니다.
Virax Biolabs Group (Nasdaq: VRAX), une entreprise de biotechnologie axée sur la détection de la réponse immunitaire et le diagnostic des maladies virales, a annoncé une offre directe enregistrée de 5 millions de dollars pour 1.108.892 actions ordinaires au prix de 4,50 dollars par action.
H.C. Wainwright & Co. est l'agent de placement exclusif. L'offre devrait se clôturer aux alentours du 23 août 2024, sous réserve des conditions habituelles.
Les produits bruts sont estimés à 5 millions de dollars, avant frais de placement et dépenses. Les produits nets sont destinés à des fonds de roulement et des fins d'entreprise générales.
L'offre est effectuée en vertu d'une déclaration d'enregistrement de type étagère (Formulaire F-3, Numéro d'enregistrement 333-275893), précédemment déposée auprès de la SEC et déclarée effective le 15 décembre 2023. Un supplément au prospectus final et le prospectus de base seront déposés et rendus disponibles sur le site de la SEC.
Virax Biolabs Group (Nasdaq: VRAX), ein biotechnologisches Unternehmen, das sich auf die Erkennung von Immunantworten und die Diagnostik von Viruskrankheiten konzentriert, hat ein registriertes Direktangebot von 5 Millionen Dollar über 1.108.892 Stammaktien zu je 4,50 Dollar pro Aktie angekündigt.
H.C. Wainwright & Co. ist der exklusive Platzierungsagent. Das Angebot soll voraussichtlich am oder um den 23. August 2024 abgeschlossen werden, vorbehaltlich der üblichen Bedingungen.
Die Bruttoeinnahmen werden vor Platzierungsgebühren und Ausgaben auf 5 Millionen Dollar geschätzt. Die Nettoerlöse sollen für Betriebskapital und allgemeine Unternehmenszwecke verwendet werden.
Das Angebot erfolgt im Rahmen eines Regal-Registrierungsantrags (Formular F-3, Registrierungsnummer 333-275893), der zuvor bei der SEC eingereicht und am 15. Dezember 2023 für wirksam erklärt wurde. Ein endgültiger Prospektnachtrag und der Basisprospekt werden eingereicht und auf der SEC-Website verfügbar gemacht.
- Virax Biolabs secures $5 million in gross proceeds.
- Proceeds aimed at strengthening working capital and general corporate purposes.
- Potential shareholder dilution from the issuance of 1,108,892 new shares.
Virax Biolabs'
As a biotech focused on viral disease detection, Virax Biolabs operates in a highly competitive and rapidly evolving field. The
The timing of Virax's offering is intriguing, coming amidst a challenging market for biotech fundraising. The
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately
The securities described above are being offered and sold by the Company pursuant to a "shelf" registration statement on Form F-3 (Registration No. 333-275893), including a base prospectus, previously filed with the Securities and Exchange Commission ("SEC") on December 5, 2023, and declared effective by the SEC on December 15, 2023. The securities to be issued in the registered direct offering are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to, and describing the terms of, the registered direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the registered direct offering, when available, may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor,
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: statements related to the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering, the intended use of proceeds from the registered direct offering, our financial performance and projections, our growth in revenue and earnings, and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: market and other conditions; our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2024. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson and Adanna Alexander
12 West 27th Street
4th Floor
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-5-million-registered-direct-offering-of-ordinary-shares-302228064.html
SOURCE Virax Biolabs
FAQ
What is the value of the registered direct offering by Virax Biolabs?
How many shares are being issued in Virax Biolabs' offering?
What is the price per share in the Virax Biolabs' offering?
When is the closing date for Virax Biolabs' offering?
What will Virax Biolabs use the net proceeds from the offering for?
Who is the placement agent for Virax Biolabs' offering?